Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PIK3CA H1047R |
| Therapy | Buparlisib + Cediranib |
| Indication/Tumor Type | endometrial mixed adenocarcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PIK3CA H1047R | endometrial mixed adenocarcinoma | sensitive | Buparlisib + Cediranib | Preclinical - Pdx & cell culture | Actionable | In a preclinical study, treatment with the combination of Buparlisib (BKM120) and Cediranib (AZD-2171) synergistically inhibited viability of a patient-derived organoid model of endometrial mixed adenocarcinoma harboring PIK3CA H1047R in culture and inhibited tumor growth in a patient-derived xenograft (PDX) model (PMID: 41886729). | 41886729 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (41886729) | Preclinical Combination Targeting VEGF and PI3K in a Rare, Aggressive Mixed Endometrial Carcinoma: An Applied Case Report. | Full reference... |